Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis
The aim of this retrospective study was to evaluate the toxicity profiles of dasatinib in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphatic leukemia (ALL) who were intolerant to imatinib, and who had been enrolled in our previous clinical trials to eval...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2011-06, Vol.93 (6), p.745-749 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 749 |
|---|---|
| container_issue | 6 |
| container_start_page | 745 |
| container_title | International journal of hematology |
| container_volume | 93 |
| creator | Kobayashi, Yukio Sakamaki, Hisashi Fujisawa, Shin Ando, Kiyoshi Yamamoto, Kazuhito Okada, Masaya Ishizawa, Kenichi Nagai, Tadashi Miyawaki, Syuichi Motoji, Toshiko Usui, Noriko Iida, Shinsuke Taniwaki, Masafumi Uoshima, Nobuhiko Seriu, Taku Ohno, Ryuzo |
| description | The aim of this retrospective study was to evaluate the toxicity profiles of dasatinib in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphatic leukemia (ALL) who were intolerant to imatinib, and who had been enrolled in our previous clinical trials to evaluate efficacy of dasatinib in patients resistant or tolerant to imatinib therapy. Twenty-four patients with CML and four with ALL were enrolled in the clinical studies to evaluate the efficacy according to the eligibility criteria related to intolerance to imatinib therapy. The toxicities reported during imatinib therapy were non-hematological toxicities in 23 patients and hematological toxicities in six patients. Patients were administered dasatinib 50–70 mg BID or 100 mg QD. Cross intolerance was observed in four patients who showed hematological toxicity after dasatinib treatment. However, it was possible to successfully continue therapy with only temporary interruption. No cross intolerance in non-hematological toxicity was found with the exception of one patient who showed cross intolerance, which did not result in treatment interruption. Dasatinib can be safely administered to imatinib-intolerant CML or Ph-positive ALL patients. |
| doi_str_mv | 10.1007/s12185-011-0864-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1753470156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2368778671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-15ad45a8ab08698f7f73d62d37c38f0174c1d7bf179efe27705a7f4cd13ac6ff3</originalsourceid><addsrcrecordid>eNp1kd-K1DAUh4so7rj6AN5IEARvqjlt0nS8Wxb_wYBe6HXJpCfb7KZJTVKlb-ujmM6MsyB4lXDynV8O5yuK50DfAKXibYQKWl5SgJK2DSvhQbGBtuFlLQR7WGzotuIlF0Aviicx3lIKgjLxuLiogG-ZaOpN8Xsn1R3xmjjvygFHmbz1N0ZJS1TwMRLjcgWDdApXrJdRJuPMniRPzHi6G3e-l-eGRKZcQpci-WXSQL4Oxsoe7TQYSdQQ_OijH5FMPppkfuKh5owi44LWm55YnO9wzLAPRKo5IbHLOA05VJ3f3hFJAqY86oTqkBKlxrQQ6aRdoolPi0da2ojPTudl8f3D-2_Xn8rdl4-fr692pWJtk0rgsmdctnKfN7lttdCi7puqr4WqW50XxxT0Yq9BbFFjJQTlUmimeqilarSuL4vXx9wp-B8zxtSNJiq0Vjr0c-xA8JoJCrzJ6Mt_0Fs_hzxv7Nqcy0UNbYbgCB00BNTdFPKOw9IB7Vb73dF-l-13q_0Ocs-LU_C8H7E_d_zVnYFXJ0DGrFivWk285xhndNuuQdWRi_nJ3WC4n_D_v_8B_NnOZw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>870557318</pqid></control><display><type>article</type><title>Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kobayashi, Yukio ; Sakamaki, Hisashi ; Fujisawa, Shin ; Ando, Kiyoshi ; Yamamoto, Kazuhito ; Okada, Masaya ; Ishizawa, Kenichi ; Nagai, Tadashi ; Miyawaki, Syuichi ; Motoji, Toshiko ; Usui, Noriko ; Iida, Shinsuke ; Taniwaki, Masafumi ; Uoshima, Nobuhiko ; Seriu, Taku ; Ohno, Ryuzo</creator><creatorcontrib>Kobayashi, Yukio ; Sakamaki, Hisashi ; Fujisawa, Shin ; Ando, Kiyoshi ; Yamamoto, Kazuhito ; Okada, Masaya ; Ishizawa, Kenichi ; Nagai, Tadashi ; Miyawaki, Syuichi ; Motoji, Toshiko ; Usui, Noriko ; Iida, Shinsuke ; Taniwaki, Masafumi ; Uoshima, Nobuhiko ; Seriu, Taku ; Ohno, Ryuzo</creatorcontrib><description>The aim of this retrospective study was to evaluate the toxicity profiles of dasatinib in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphatic leukemia (ALL) who were intolerant to imatinib, and who had been enrolled in our previous clinical trials to evaluate efficacy of dasatinib in patients resistant or tolerant to imatinib therapy. Twenty-four patients with CML and four with ALL were enrolled in the clinical studies to evaluate the efficacy according to the eligibility criteria related to intolerance to imatinib therapy. The toxicities reported during imatinib therapy were non-hematological toxicities in 23 patients and hematological toxicities in six patients. Patients were administered dasatinib 50–70 mg BID or 100 mg QD. Cross intolerance was observed in four patients who showed hematological toxicity after dasatinib treatment. However, it was possible to successfully continue therapy with only temporary interruption. No cross intolerance in non-hematological toxicity was found with the exception of one patient who showed cross intolerance, which did not result in treatment interruption. Dasatinib can be safely administered to imatinib-intolerant CML or Ph-positive ALL patients.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-011-0864-1</identifier><identifier>PMID: 21594763</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Benzamides ; Biological and medical sciences ; Dasatinib ; Drug toxicity and drugs side effects treatment ; Hematologic and hematopoietic diseases ; Hematologic Diseases - etiology ; Hematology ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Oncology ; Original Article ; Pharmacology. Drug treatments ; Piperazines - administration & dosage ; Piperazines - adverse effects ; Piperazines - therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Pyrimidines - administration & dosage ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Retrospective Studies ; Thiazoles - administration & dosage ; Thiazoles - adverse effects ; Thiazoles - therapeutic use</subject><ispartof>International journal of hematology, 2011-06, Vol.93 (6), p.745-749</ispartof><rights>The Japanese Society of Hematology 2011</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-15ad45a8ab08698f7f73d62d37c38f0174c1d7bf179efe27705a7f4cd13ac6ff3</citedby><cites>FETCH-LOGICAL-c486t-15ad45a8ab08698f7f73d62d37c38f0174c1d7bf179efe27705a7f4cd13ac6ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-011-0864-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-011-0864-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24540981$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21594763$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kobayashi, Yukio</creatorcontrib><creatorcontrib>Sakamaki, Hisashi</creatorcontrib><creatorcontrib>Fujisawa, Shin</creatorcontrib><creatorcontrib>Ando, Kiyoshi</creatorcontrib><creatorcontrib>Yamamoto, Kazuhito</creatorcontrib><creatorcontrib>Okada, Masaya</creatorcontrib><creatorcontrib>Ishizawa, Kenichi</creatorcontrib><creatorcontrib>Nagai, Tadashi</creatorcontrib><creatorcontrib>Miyawaki, Syuichi</creatorcontrib><creatorcontrib>Motoji, Toshiko</creatorcontrib><creatorcontrib>Usui, Noriko</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><creatorcontrib>Taniwaki, Masafumi</creatorcontrib><creatorcontrib>Uoshima, Nobuhiko</creatorcontrib><creatorcontrib>Seriu, Taku</creatorcontrib><creatorcontrib>Ohno, Ryuzo</creatorcontrib><title>Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>The aim of this retrospective study was to evaluate the toxicity profiles of dasatinib in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphatic leukemia (ALL) who were intolerant to imatinib, and who had been enrolled in our previous clinical trials to evaluate efficacy of dasatinib in patients resistant or tolerant to imatinib therapy. Twenty-four patients with CML and four with ALL were enrolled in the clinical studies to evaluate the efficacy according to the eligibility criteria related to intolerance to imatinib therapy. The toxicities reported during imatinib therapy were non-hematological toxicities in 23 patients and hematological toxicities in six patients. Patients were administered dasatinib 50–70 mg BID or 100 mg QD. Cross intolerance was observed in four patients who showed hematological toxicity after dasatinib treatment. However, it was possible to successfully continue therapy with only temporary interruption. No cross intolerance in non-hematological toxicity was found with the exception of one patient who showed cross intolerance, which did not result in treatment interruption. Dasatinib can be safely administered to imatinib-intolerant CML or Ph-positive ALL patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Dasatinib</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematologic Diseases - etiology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - administration & dosage</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - therapeutic use</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Thiazoles - administration & dosage</subject><subject>Thiazoles - adverse effects</subject><subject>Thiazoles - therapeutic use</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kd-K1DAUh4so7rj6AN5IEARvqjlt0nS8Wxb_wYBe6HXJpCfb7KZJTVKlb-ujmM6MsyB4lXDynV8O5yuK50DfAKXibYQKWl5SgJK2DSvhQbGBtuFlLQR7WGzotuIlF0Aviicx3lIKgjLxuLiogG-ZaOpN8Xsn1R3xmjjvygFHmbz1N0ZJS1TwMRLjcgWDdApXrJdRJuPMniRPzHi6G3e-l-eGRKZcQpci-WXSQL4Oxsoe7TQYSdQQ_OijH5FMPppkfuKh5owi44LWm55YnO9wzLAPRKo5IbHLOA05VJ3f3hFJAqY86oTqkBKlxrQQ6aRdoolPi0da2ojPTudl8f3D-2_Xn8rdl4-fr692pWJtk0rgsmdctnKfN7lttdCi7puqr4WqW50XxxT0Yq9BbFFjJQTlUmimeqilarSuL4vXx9wp-B8zxtSNJiq0Vjr0c-xA8JoJCrzJ6Mt_0Fs_hzxv7Nqcy0UNbYbgCB00BNTdFPKOw9IB7Vb73dF-l-13q_0Ocs-LU_C8H7E_d_zVnYFXJ0DGrFivWk285xhndNuuQdWRi_nJ3WC4n_D_v_8B_NnOZw</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Kobayashi, Yukio</creator><creator>Sakamaki, Hisashi</creator><creator>Fujisawa, Shin</creator><creator>Ando, Kiyoshi</creator><creator>Yamamoto, Kazuhito</creator><creator>Okada, Masaya</creator><creator>Ishizawa, Kenichi</creator><creator>Nagai, Tadashi</creator><creator>Miyawaki, Syuichi</creator><creator>Motoji, Toshiko</creator><creator>Usui, Noriko</creator><creator>Iida, Shinsuke</creator><creator>Taniwaki, Masafumi</creator><creator>Uoshima, Nobuhiko</creator><creator>Seriu, Taku</creator><creator>Ohno, Ryuzo</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope></search><sort><creationdate>20110601</creationdate><title>Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis</title><author>Kobayashi, Yukio ; Sakamaki, Hisashi ; Fujisawa, Shin ; Ando, Kiyoshi ; Yamamoto, Kazuhito ; Okada, Masaya ; Ishizawa, Kenichi ; Nagai, Tadashi ; Miyawaki, Syuichi ; Motoji, Toshiko ; Usui, Noriko ; Iida, Shinsuke ; Taniwaki, Masafumi ; Uoshima, Nobuhiko ; Seriu, Taku ; Ohno, Ryuzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-15ad45a8ab08698f7f73d62d37c38f0174c1d7bf179efe27705a7f4cd13ac6ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Dasatinib</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematologic Diseases - etiology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - administration & dosage</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - therapeutic use</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Thiazoles - administration & dosage</topic><topic>Thiazoles - adverse effects</topic><topic>Thiazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kobayashi, Yukio</creatorcontrib><creatorcontrib>Sakamaki, Hisashi</creatorcontrib><creatorcontrib>Fujisawa, Shin</creatorcontrib><creatorcontrib>Ando, Kiyoshi</creatorcontrib><creatorcontrib>Yamamoto, Kazuhito</creatorcontrib><creatorcontrib>Okada, Masaya</creatorcontrib><creatorcontrib>Ishizawa, Kenichi</creatorcontrib><creatorcontrib>Nagai, Tadashi</creatorcontrib><creatorcontrib>Miyawaki, Syuichi</creatorcontrib><creatorcontrib>Motoji, Toshiko</creatorcontrib><creatorcontrib>Usui, Noriko</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><creatorcontrib>Taniwaki, Masafumi</creatorcontrib><creatorcontrib>Uoshima, Nobuhiko</creatorcontrib><creatorcontrib>Seriu, Taku</creatorcontrib><creatorcontrib>Ohno, Ryuzo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kobayashi, Yukio</au><au>Sakamaki, Hisashi</au><au>Fujisawa, Shin</au><au>Ando, Kiyoshi</au><au>Yamamoto, Kazuhito</au><au>Okada, Masaya</au><au>Ishizawa, Kenichi</au><au>Nagai, Tadashi</au><au>Miyawaki, Syuichi</au><au>Motoji, Toshiko</au><au>Usui, Noriko</au><au>Iida, Shinsuke</au><au>Taniwaki, Masafumi</au><au>Uoshima, Nobuhiko</au><au>Seriu, Taku</au><au>Ohno, Ryuzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>93</volume><issue>6</issue><spage>745</spage><epage>749</epage><pages>745-749</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>The aim of this retrospective study was to evaluate the toxicity profiles of dasatinib in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphatic leukemia (ALL) who were intolerant to imatinib, and who had been enrolled in our previous clinical trials to evaluate efficacy of dasatinib in patients resistant or tolerant to imatinib therapy. Twenty-four patients with CML and four with ALL were enrolled in the clinical studies to evaluate the efficacy according to the eligibility criteria related to intolerance to imatinib therapy. The toxicities reported during imatinib therapy were non-hematological toxicities in 23 patients and hematological toxicities in six patients. Patients were administered dasatinib 50–70 mg BID or 100 mg QD. Cross intolerance was observed in four patients who showed hematological toxicity after dasatinib treatment. However, it was possible to successfully continue therapy with only temporary interruption. No cross intolerance in non-hematological toxicity was found with the exception of one patient who showed cross intolerance, which did not result in treatment interruption. Dasatinib can be safely administered to imatinib-intolerant CML or Ph-positive ALL patients.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>21594763</pmid><doi>10.1007/s12185-011-0864-1</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2011-06, Vol.93 (6), p.745-749 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1753470156 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Dasatinib Drug toxicity and drugs side effects treatment Hematologic and hematopoietic diseases Hematologic Diseases - etiology Hematology Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Medicine Medicine & Public Health Middle Aged Miscellaneous (drug allergy, mutagens, teratogens...) Oncology Original Article Pharmacology. Drug treatments Piperazines - administration & dosage Piperazines - adverse effects Piperazines - therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Retrospective Studies Thiazoles - administration & dosage Thiazoles - adverse effects Thiazoles - therapeutic use |
| title | Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T23%3A19%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lack%20of%20non-hematological%20cross%20intolerance%20of%20dasatinib%20to%20imatinib%20in%20imatinib-intolerant%20patients%20with%20Philadelphia%20chromosome%20positive%20chronic%20myeloid%20leukemia%20or%20acute%20lymphatic%20leukemia:%20a%20retrospective%20safety%20analysis&rft.jtitle=International%20journal%20of%20hematology&rft.au=Kobayashi,%20Yukio&rft.date=2011-06-01&rft.volume=93&rft.issue=6&rft.spage=745&rft.epage=749&rft.pages=745-749&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-011-0864-1&rft_dat=%3Cproquest_cross%3E2368778671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=870557318&rft_id=info:pmid/21594763&rfr_iscdi=true |